[Breaking] 'Botulinum Lawsuit' 1st Trial: "Daewoong Pharmaceutical to Pay Medytox 40 Billion Won"
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2020121811104873218_1608257448.jpg)
[Asia Economy Reporter Kim Daehyun] Daewoong Pharmaceutical has effectively lost the first trial in a civil lawsuit filed by Medytox, which claimed that its botulinum toxin strain was stolen.
On the afternoon of the 10th, the Civil Division 61 of the Seoul Central District Court (Presiding Judge Kwon O-seok) ruled partially in favor of the plaintiff in the first trial of a lawsuit filed by Medytox against Daewoong Pharmaceutical, seeking to prohibit trade secret infringement worth about 50 billion won. The court ordered Daewoong Pharmaceutical to pay Medytox 40 billion won and to dispose of finished products made using some of the strains.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Botulinum preparations are biopharmaceuticals mainly used in cosmetic procedures such as glabellar wrinkle improvement. In 2017, Medytox filed a lawsuit suspecting Daewoong Pharmaceutical of stealing the strain.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
